Literature DB >> 29557907

Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation.

Lisa B VanWagner1,2,3, Samantha Montag2, Lihui Zhao2, Norrina B Allen2, Donald M Lloyd-Jones2,4, Arighno Das1, Anton I Skaro5, Samuel Hohmann6, John J Friedewald3,7, Josh Levitsky1,3.   

Abstract

BACKGROUND: In the general population, even mild renal disease is associated with increased cardiovascular (CV) complications. Whether this is true in liver transplant recipients (LTR) is unknown.
METHODS: This was a retrospective cohort study of 671 LTR (2002-2012) from a large urban tertiary care center and 37 322 LTR using Vizient hospitalization data linked to the United Network for Organ Sharing. The 4-variable Modification of Diet in Renal Disease equation estimated glomerular filtration rate (eGFR). Outcomes were 1-year CV complications (death/hospitalization from myocardial infarction, heart failure, atrial fibrillation, cardiac arrest, pulmonary embolism, or stroke) and mortality. Latent mixture modeling identified trajectories in eGFR in the first liver transplantation (LT) year in the 671 patients.
RESULTS: Mean (SD) eGFR was 72.1 (45.7) mL/min per 1.73 m. Six distinct eGFR trajectories were identified in the local cohort (n = 671): qualitatively normal-slow decrease (4% of cohort), normal-rapid decrease (4%), mild-stable (18%), mild-slow decrease (35%), moderate-stable (30%), and severe-stable (9%). In multivariable analyses adjusted for confounders and baseline eGFR, the greatest odds of 1-year CV complications were in the normal-rapid decrease group (odds ratio, 10.6; 95% confidence interval, 3.0-36.9). Among the national cohort, each 5-unit lower eGFR at LT was associated with a 2% and 5% higher hazard of all-cause and CV-mortality, respectively (P < 0.0001), independent of multiple confounders.
CONCLUSIONS: Even mild renal disease at the time of LT is a risk factor for posttransplant all-cause and CV mortality. More rapid declines in eGFR soon after LT correlate with risk of adverse CV outcomes, highlighting the need to study whether early renal preservation interventions also reduce CV complications.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29557907      PMCID: PMC6023752          DOI: 10.1097/TP.0000000000002175

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  48 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function.

Authors:  M Masetti; R Montalti; G Rompianesi; M Codeluppi; R Gerring; A Romano; B Begliomini; F Di Benedetto; G E Gerunda
Journal:  Am J Transplant       Date:  2010-09-03       Impact factor: 8.086

3.  Predictive factors for chronic renal failure one year after orthotopic liver transplantation.

Authors:  Joelle Guitard; David Ribes; Nassim Kamar; Fabrice Muscari; Olivier Cointault; Laurence Lavayssière; Bertrand Suc; Laure Esposito; Jean-Marie Peron; Lionel Rostaing
Journal:  Ren Fail       Date:  2006       Impact factor: 2.606

4.  Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.

Authors:  Satheesh Nair; Sumita Verma; Paul J Thuluvath
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

5.  Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.

Authors:  Gary Levy; Heinz Schmidli; Jeffrey Punch; Elizabeth Tuttle-Newhall; David Mayer; Peter Neuhaus; Didier Samuel; Bjorn Nashan; Juergen Klempnauer; Alan Langnas; Yvon Calmus; Xavier Rogiers; Michael Abecassis; Richard Freeman; Maarten Sloof; John Roberts; Lutz Fischer
Journal:  Liver Transpl       Date:  2006-11       Impact factor: 5.799

6.  Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients.

Authors:  Yvon Calmus; Nassim Kamar; Jean Gugenheim; Christophe Duvoux; Christian Ducerf; Philippe Wolf; Didier Samuel; Claire Vanlemmens; Martine Neau-Cransac; Ephrem Salamé; Olivier Chazouillères; Nicole Declerck; Georges-Philippe Pageaux; Laurence Dubel; Lionel Rostaing
Journal:  Transplantation       Date:  2010-06-27       Impact factor: 4.939

7.  A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT.

Authors:  L Fischer; J Klempnauer; S Beckebaum; H J Metselaar; P Neuhaus; P Schemmer; U Settmacher; N Heyne; P-A Clavien; F Muehlbacher; I Morard; H Wolters; W Vogel; T Becker; M Sterneck; F Lehner; C Klein; G Kazemier; A Pascher; J Schmidt; F Rauchfuss; A Schnitzbauer; S Nadalin; M Hack; S Ladenburger; H J Schlitt
Journal:  Am J Transplant       Date:  2012-04-11       Impact factor: 8.086

8.  A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.

Authors:  Alejandra Otero; Evaristo Varo; Jorge Ortiz de Urbina; Rafael Martín-Vivaldi; Valentin Cuervas-Mons; Ignacio González-Pinto; Antoni Rimola; Angel Bernardos; Santiago Otero; Jorge Maldonado; Jose I Herrero; Elena Barrao; Rosa Domínguez-Granados
Journal:  Liver Transpl       Date:  2009-11       Impact factor: 5.799

9.  A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Authors:  Christopher J E Watson; Alexander E S Gimson; Graeme J Alexander; Michael E D Allison; Paul Gibbs; Jane C Smith; Christopher R Palmer; J Andrew Bradley
Journal:  Liver Transpl       Date:  2007-12       Impact factor: 5.799

10.  Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.

Authors:  P De Simone; F Nevens; L De Carlis; H J Metselaar; S Beckebaum; F Saliba; S Jonas; D Sudan; J Fung; L Fischer; C Duvoux; K D Chavin; B Koneru; M A Huang; W C Chapman; D Foltys; S Witte; H Jiang; J M Hexham; G Junge
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

View more
  9 in total

1.  The Impact of Renal Insufficiency After Liver Transplantation.

Authors:  Hillary J Braun; Nancy L Ascher
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

2.  Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients.

Authors:  Lisa B VanWagner; Jane L Holl; Samantha Montag; Dyanna Gregory; Sean Connolly; Megan Kosirog; Patrick Campbell; Stewart Pine; Amna Daud; Dan Finn; Daniela Ladner; Anton I Skaro; Josh Levitsky; Donald M Lloyd-Jones
Journal:  Am J Transplant       Date:  2019-12-09       Impact factor: 8.086

Review 3.  Long-term Management of the Adult Liver Transplantation Recipients.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-07-02

Review 4.  Medical management of metabolic and cardiovascular complications after liver transplantation.

Authors:  Chiara Becchetti; Melisa Dirchwolf; Vanessa Banz; Jean-François Dufour
Journal:  World J Gastroenterol       Date:  2020-05-14       Impact factor: 5.742

Review 5.  Metabolic associated fatty liver disease: Addressing a new era in liver transplantation.

Authors:  Madeleine G Gill; Avik Majumdar
Journal:  World J Hepatol       Date:  2020-12-27

6.  The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients.

Authors:  Lydia Sastre; Raquel García; Julián-Gonzalo Gándara; Patricia Fernández-Llama; Antonio J Amor; Cristina Sierra; Laia Escudé; Pablo Ruiz; Jordi Colmenero; Emilio Ortega; Miquel Navasa; Gonzalo Crespo
Journal:  Transplant Direct       Date:  2021-12-23

7.  Non-Renal Risk Factors for Chronic Kidney Disease in Liver Recipients with Functionally Intact Kidneys at 1 Month.

Authors:  Deok-Gie Kim; Shin Hwang; Jong Man Kim; Je Ho Ryu; Young Kyoung You; Donglak Choi; Bong-Wan Kim; Dong-Sik Kim; Yang Won Nah; Tae-Seok Kim; Jai Young Cho; Geun Hong; Jae Do Yang; Jaryung Han; Suk-Won Suh; Kwan Woo Kim; Yun Kyung Jung; Ju Ik Moon; Jun Young Lee; Sung Hwa Kim; Jae Geun Lee; Myoung Soo Kim; Kwang-Woong Lee; Dong Jin Joo
Journal:  J Clin Med       Date:  2022-07-20       Impact factor: 4.964

8.  A systematic review of statistical methodology used to evaluate progression of chronic kidney disease using electronic healthcare records.

Authors:  Faye Cleary; David Prieto-Merino; Dorothea Nitsch
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

9.  Liver transplantation and atrial fibrillation: A meta-analysis.

Authors:  Ronpichai Chokesuwattanaskul; Charat Thongprayoon; Tarun Bathini; Patompong Ungprasert; Konika Sharma; Karn Wijarnpreecha; Pavida Pachariyanon; Wisit Cheungpasitporn
Journal:  World J Hepatol       Date:  2018-10-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.